Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.

Román M, López I, Guruceaga E, Baraibar I, Ecay M, Collantes M, Nadal E, Vallejo A, Cadenas S, Miguel ME, Jang JH, Martin-Uriz PS, Castro-Labrador L, Vilas-Zornoza A, Lara-Astiaso D, Ponz-Sarvise M, Rolfo C, Santos ES, Raez LE, Taverna S, Behrens C, Weder W, Wistuba II, Vicent S, Gil-Bazo I.

Cancer Res. 2019 Feb 1;79(3):625-638. doi: 10.1158/0008-5472.CAN-18-1479. Epub 2018 Dec 18.

PMID:
30563891
2.

Adjuvant Therapy for Colon Cancer: Genes, Genes… and the Patient in the Center.

Rodriguez J, Vicent S, Chopitea A, Ponz-Sarvisé M.

Clin Cancer Res. 2018 Aug 15;24(16):3787-3789. doi: 10.1158/1078-0432.CCR-18-0818. Epub 2018 Apr 20.

PMID:
29678903
3.

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.

Román M, Baraibar I, López I, Nadal E, Rolfo C, Vicent S, Gil-Bazo I.

Mol Cancer. 2018 Feb 19;17(1):33. doi: 10.1186/s12943-018-0789-x. Review.

4.

Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects.

Ajona D, Zandueta C, Corrales L, Moreno H, Pajares MJ, Ortiz-Espinosa S, Martínez-Terroba E, Perurena N, de Miguel FJ, Jantus-Lewintre E, Camps C, Vicent S, Agorreta J, Montuenga LM, Pio R, Lecanda F.

Am J Respir Crit Care Med. 2018 May 1;197(9):1164-1176. doi: 10.1164/rccm.201703-0660OC.

PMID:
29327939
5.

All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS.

Vallejo A, Valencia K, Vicent S.

Mol Cell Oncol. 2017 Apr 5;4(3):e1314239. doi: 10.1080/23723556.2017.1314239. eCollection 2017.

6.

A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.

Ajona D, Ortiz-Espinosa S, Moreno H, Lozano T, Pajares MJ, Agorreta J, Bértolo C, Lasarte JJ, Vicent S, Hoehlig K, Vater A, Lecanda F, Montuenga LM, Pio R.

Cancer Discov. 2017 Jul;7(7):694-703. doi: 10.1158/2159-8290.CD-16-1184. Epub 2017 Mar 13.

7.

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.

Vallejo A, Perurena N, Guruceaga E, Mazur PK, Martinez-Canarias S, Zandueta C, Valencia K, Arricibita A, Gwinn D, Sayles LC, Chuang CH, Guembe L, Bailey P, Chang DK, Biankin A, Ponz-Sarvise M, Andersen JB, Khatri P, Bozec A, Sweet-Cordero EA, Sage J, Lecanda F, Vicent S.

Nat Commun. 2017 Feb 21;8:14294. doi: 10.1038/ncomms14294.

8.

EPCR promotes breast cancer progression by altering SPOCK1/testican 1-mediated 3D growth.

Perurena N, Zandueta C, Martínez-Canarias S, Moreno H, Vicent S, Almeida AS, Guruceaga E, Gomis RR, Santisteban M, Egeblad M, Hermida J, Lecanda F.

J Hematol Oncol. 2017 Jan 19;10(1):23. doi: 10.1186/s13045-017-0399-x.

9.

The present and the future of the RAS pathway: From function and genomics to inhibition.

Gil-Bazo I, Sweet-Cordero A, Vicent S.

Cancer Biol Ther. 2016 Jul 2;17(7):719-22. doi: 10.1080/15384047.2016.1190487. Epub 2016 May 21.

10.

Matrix-Gla protein promotes osteosarcoma lung metastasis and associates with poor prognosis.

Zandueta C, Ormazábal C, Perurena N, Martínez-Canarias S, Zalacaín M, Julián MS, Grigoriadis AE, Valencia K, Campos-Laborie FJ, Rivas Jde L, Vicent S, Patiño-García A, Lecanda F.

J Pathol. 2016 Aug;239(4):438-49. doi: 10.1002/path.4740. Epub 2016 Jun 29.

PMID:
27172275
11.

Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression.

Urtasun R, Elizalde M, Azkona M, Latasa MU, García-Irigoyen O, Uriarte I, Fernández-Barrena MG, Vicent S, Alonso MM, Muntané J, Prieto J, Ávila MA, Berasain C.

Oncogene. 2016 Sep 8;35(36):4719-29. doi: 10.1038/onc.2015.517. Epub 2016 Jan 25.

PMID:
26804174
12.

Bone metastases in lung cancer. Potential novel approaches to therapy.

Vicent S, Perurena N, Govindan R, Lecanda F.

Am J Respir Crit Care Med. 2015 Oct 1;192(7):799-809. doi: 10.1164/rccm.201503-0440SO. Review.

PMID:
26131844
13.

A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma.

Chen R, Khatri P, Mazur PK, Polin M, Zheng Y, Vaka D, Hoang CD, Shrager J, Xu Y, Vicent S, Butte AJ, Sweet-Cordero EA.

Cancer Res. 2014 May 15;74(10):2892-902. doi: 10.1158/0008-5472.CAN-13-2775. Epub 2014 Mar 20.

14.

RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner.

Luis-Ravelo D, Antón I, Zandueta C, Valencia K, Pajares MJ, Agorreta J, Montuenga L, Vicent S, Wistuba II, De Las Rivas J, Lecanda F.

Mol Oncol. 2014 Mar;8(2):196-206. doi: 10.1016/j.molonc.2013.11.001. Epub 2013 Nov 12.

15.

A gene signature of bone metastatic colonization sensitizes for tumor-induced osteolysis and predicts survival in lung cancer.

Luis-Ravelo D, Antón I, Zandueta C, Valencia K, Ormazábal C, Martínez-Canarias S, Guruceaga E, Perurena N, Vicent S, De Las Rivas J, Lecanda F.

Oncogene. 2014 Oct 23;33(43):5090-9. doi: 10.1038/onc.2013.440. Epub 2013 Oct 28.

PMID:
24166494
16.

Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo.

Vicent S, Sayles LC, Vaka D, Khatri P, Gevaert O, Chen R, Zheng Y, Gillespie AK, Clarke N, Xu Y, Shrager J, Hoang CD, Plevritis S, Butte AJ, Sweet-Cordero EA.

Cancer Res. 2012 Nov 15;72(22):5744-56. doi: 10.1158/0008-5472.CAN-12-1097. Epub 2012 Sep 7.

17.

Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis.

Tran PT, Shroff EH, Burns TF, Thiyagarajan S, Das ST, Zabuawala T, Chen J, Cho YJ, Luong R, Tamayo P, Salih T, Aziz K, Adam SJ, Vicent S, Nielsen CH, Withofs N, Sweet-Cordero A, Gambhir SS, Rudin CM, Felsher DW.

PLoS Genet. 2012;8(5):e1002650. doi: 10.1371/journal.pgen.1002650. Epub 2012 May 24.

18.

MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.

Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M.

Cancer Res. 2012 Jun 15;72(12):3048-59. doi: 10.1158/0008-5472.CAN-11-3649. Epub 2012 Apr 17.

19.

Tumor-stromal interactions of the bone microenvironment: in vitro findings and potential in vivo relevance in metastatic lung cancer models.

Luis-Ravelo D, Antón I, Vicent S, Hernández I, Valencia K, Zandueta C, Martínez-Canarias S, Gúrpide A, Lecanda F.

Clin Exp Metastasis. 2011 Dec;28(8):779-91. doi: 10.1007/s10585-011-9409-5. Epub 2011 Jul 28.

PMID:
21796372
20.

Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.

Vicent S, Chen R, Sayles LC, Lin C, Walker RG, Gillespie AK, Subramanian A, Hinkle G, Yang X, Saif S, Root DE, Huff V, Hahn WC, Sweet-Cordero EA.

J Clin Invest. 2010 Nov;120(11):3940-52. doi: 10.1172/JCI44165. Epub 2010 Oct 25.

21.

A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism.

Vicent S, Luis-Ravelo D, Antón I, García-Tuñón I, Borrás-Cuesta F, Dotor J, De Las Rivas J, Lecanda F.

Cancer Res. 2008 Apr 1;68(7):2275-85. doi: 10.1158/0008-5472.CAN-07-6493.

22.

Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway.

Blanco D, Vicent S, Fraga MF, Fernandez-Garcia I, Freire J, Lujambio A, Esteller M, Ortiz-de-Solorzano C, Pio R, Lecanda F, Montuenga LM.

Neoplasia. 2007 Oct;9(10):840-52.

23.

EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model.

González I, Vicent S, de Alava E, Lecanda F.

J Mol Med (Berl). 2007 Sep;85(9):1015-29. Epub 2007 Apr 24.

PMID:
17453169
24.

[Bone metastases].

Vicent S, Luis-Ravelo D, Antón I, Hernández I, Martínez S, de las Rivas J, Gúrpide A, Lecanda F.

An Sist Sanit Navar. 2006 May-Aug;29(2):177-88. Spanish.

25.

Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer.

Pio R, Zudaire I, Pino I, Castaño Z, Zabalegui N, Vicent S, Garcia-Amigot F, Odero MD, Lozano MD, Garcia-Foncillas J, Calasanz MJ, Montuenga LM.

Cancer Res. 2004 Jun 15;64(12):4171-9.

26.

Altered expression of adhesion molecules and epithelial-mesenchymal transition in silica-induced rat lung carcinogenesis.

Blanco D, Vicent S, Elizegi E, Pino I, Fraga MF, Esteller M, Saffiotti U, Lecanda F, Montuenga LM.

Lab Invest. 2004 Aug;84(8):999-1012.

27.

Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.

Vicent S, Garayoa M, López-Picazo JM, Lozano MD, Toledo G, Thunnissen FB, Manzano RG, Montuenga LM.

Clin Cancer Res. 2004 Jun 1;10(11):3639-49.

28.

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

Vicent S, López-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchón C, Quero C, Soria JC, Martín-Algarra S, Manzano RG, Montuenga LM.

Br J Cancer. 2004 Mar 8;90(5):1047-52.

29.

Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer.

Pino I, Pío R, Toledo G, Zabalegui N, Vicent S, Rey N, Lozano MD, Torre W, García-Foncillas J, Montuenga LM.

Lung Cancer. 2003 Aug;41(2):131-43.

30.

CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential.

Manzano RG, Montuenga LM, Dayton M, Dent P, Kinoshita I, Vicent S, Gardner GJ, Nguyen P, Choi YH, Trepel J, Auersperg N, Birrer MJ.

Oncogene. 2002 Jun 27;21(28):4435-47.

31.
32.
33.

Pressures in the sphincter of Oddi in patients with gallstones, common duct stones, and recurrent pancreatitis.

Guelrud M, Mendoza S, Vicent S, Gomez M, Villalta B.

J Clin Gastroenterol. 1983 Feb;5(1):37-41.

PMID:
6841947

Supplemental Content

Loading ...
Support Center